Xiantong Pharmaceuticals Secures Over RMB 1.1 Billion in New Financing to Advance Radiopharmaceutical Pipeline

VCBeat has learned that, recently,Beijing Xiantong International Technology Co., Ltd. (hereinafter referred to as “Xiantong Pharma”) announced the completion of a new round of financing exceeding RMB 1.1 billion. This round was jointly invested by numerous state-backed funds, industrial groups, and renowned investment institutions, including SDIC Venture Capital, Jinshi Investment, National Adjustment Fund, Genertec Venture Capital, CITIC Securities Investment, Xi Venture Capital, SDIC Chuangyi, Yueke Financial Group, Jimin Kexin Investment, GF Qianhe, Wuxi Xinshang Capital, Jianggen Capital, Qingshi Capital, Chengming Capital, Zhizhong Investment, Zhongshan Venture Capital, Enran Venture Capital, and Wuhan Lide. Existing shareholders such as China Life Equity Investment and Hetang Venture Capital continued to increase their shareholdings. Kaicheng Capital served as the exclusive financial advisor for this transaction.The funds raised in this round will continue to be used for the research, development, and clinical application of diagnostic and therapeutic radiopharmaceuticals, bringing health benefits to patients in China. It is reported that this is also the largest market-oriented financing completed in the pharmaceutical sector since 2023, fully reflecting the high recognition of Xiantong Pharma by the capital market.

Beijing Xiantong International Technology Co., Ltd. is an innovative pharmaceutical company specializing in the research and development, manufacturing, clinical application, and academic promotion of radiopharmaceuticals. Headquartered in Beijing, the capital of China, it operates modern R&D centers and production bases in Shanghai, Jiangsu, Guangdong, Sichuan, and other regions, maintains a branch in the United States, and has established partnerships with more than ten multinational pharmaceutical companies.

Radiopharmaceuticals are a special class of drugs that utilize radiation (alpha, beta, and gamma rays) emitted by radionuclides to achieve early disease diagnosis and targeted therapy. As the cornerstone of nuclear medicine, radiopharmaceuticals are essential for the diagnosis and treatment of various complex and refractory diseases.

Leveraging globally leading R&D resources for precision theranostics with radiopharmaceuticals, and through independent innovation and external collaborations, Xiantong Pharma has pioneered the development of over ten targeted therapeutic and precision diagnostic radiopharmaceuticals in areas such as cardiovascular diseases, Alzheimer’s disease, and oncology. The company has accumulated extensive experience in radiopharmaceutical R&D, clinical trials, regulatory submissions, manufacturing, and commercialization. It is expected that its Aβ-PET imaging agent for the diagnosis of Alzheimer’s disease will receive marketing approval in China within this year. Together with various targeted therapeutic agents, it will provide patients with an integrated precision theranostic solution, facilitating early diagnosis and early treatment to help prevent disease onset or delay its progression throughout the patient’s lifetime.

SDIC Venture CapitalIt stated: “Nuclear medicine is a vital component of the national healthcare security system. As advanced therapy products, modern radiopharmaceuticals offer unique theranostic solutions for diseases, leading traditional radiotherapy into an era of precise targeting. They possess irreplaceable clinical advantages over other conventional therapies, particularly in the diagnosis, treatment, and prognostic evaluation of various conditions, including cardiovascular diseases, neurodegenerative disorders, and malignant tumors. As a leading enterprise in the innovative R&D of radiopharmaceuticals, Beijing Xiantong International Technology Co., Ltd. has multiple products at the forefront of the field. Their market launch has filled gaps in the domestic market, achieving a breakthrough from 0 to 1 in China’s innovative radiopharmaceutical sector. Meanwhile, leveraging its industry leadership and resource advantages, the company proactively builds and refines a specialized, high-quality full industry chain. This provides strong support for the development of China’s radiopharmaceutical industry and its participation in global competition, thereby accelerating the delivery of China’s innovative radiopharmaceutical products to patients worldwide.”

Jinshi InvestmentIt stated: “In recent years, precision diagnostics and targeted therapy using radiopharmaceuticals have become a global hotspot for development. Xiantong Medicine has taken a leading position in R&D progress in this field, with a diverse portfolio covering major disease areas addressed by radiopharmaceuticals worldwide. The company has integrated its upstream and downstream supply chain, establishing a robust system ranging from radioisotope supply to production and distribution, thereby demonstrating strong competitiveness. It is hoped that this financing round will enable Xiantong Medicine to further increase its R&D investment, accelerate the market launch of core products, and expand its product pipeline, striving to become an internationally advanced innovative radiopharmaceutical R&D enterprise and bring new directions to innovative therapies for major diseases.”

National Adjustment FundIt stated: “As a national-level private equity fund, the National Adjustment Fund prioritizes support for strategic emerging industries, including the biopharmaceutical and broader health industry chains. Radiopharmaceuticals have recently become a key focus for pharmaceutical giants and innovative drug companies, driven by supportive policies, significant inflows of capital and talent, and strong market prospects. As one of the leading enterprises in China’s innovative radiopharmaceutical sector, Xiantong Medicine possesses industry-leading capabilities in the R&D, production, and commercialization of radiopharmaceuticals. By integrating high-quality upstream and downstream resources within China’s radiopharmaceutical supply chain, the company has established core competitiveness and a rare platform advantage. This strategic investment represents an important initiative by the National Adjustment Fund to promote the development of the life sciences industry. Moving forward, the fund will support Xiantong Medicine in enhancing its R&D capabilities to provide Chinese patients with urgently needed diagnostic and therapeutic radiopharmaceutical products.”

Genertec Venture Capital“It has been stated: ‘Xiantong Pharma began its strategic layout in the field of radiopharmaceuticals in 2014. Leveraging globally leading R&D resources for precision diagnosis and therapy with radioactive drugs, the company has taken the lead in deploying a portfolio of targeted therapeutic and precision diagnostic radiopharmaceuticals in areas such as oncology, neurodegenerative diseases, and cardiovascular conditions. Meanwhile, Xiantong Pharma has integrated the highest-quality upstream and downstream industrial chain resources for radiopharmaceuticals in China, possessing significant core competitiveness and platform scarcity. We are honored to participate in this round of financing for Xiantong Pharma and look forward to working hand in hand with the company to accelerate the rapid development of China’s radiopharmaceutical industry and benefit patients.’”

China Life Equity“It has been stated: ‘In recent years, the global radiopharmaceutical market has accelerated its development. As a leading enterprise in the field of innovative radiopharmaceuticals, Beijing Xiantong International Technology Co., Ltd. boasts a product pipeline that combines innovation with commercial value. Several of its core products are on the verge of commercialization or in critical clinical stages, and the newly expanded CDMO platform is expected to further enhance the company’s multidimensional value. We fully recognize the value of the company and its products, and have continued to increase our investment in this round. We hope to support the company in achieving more clinical applications and breakthroughs in the precise diagnosis and treatment of major diseases, thereby bringing health benefits to more patients.’”

Wuxi Venture Capitalstated: “Wuxi Venture Capital Group continues to deeply explore the innovative field of targeted radiopharmaceuticals both domestically and internationally, and will maintain an active strategic layout in nuclear medicine and radiopharmaceuticals. As a leading Chinese radiopharmaceutical company, Xiantong Medicine holds significant value in driving the development of the industry chain and serves as a key long-term partner for Wuxi Venture Capital Group in this sector.””

Tang Yanmin, President of Xiantong Medicine“He expressed his sincere gratitude to all investors for their trust and support in Xiantong. With the rollout of the Medium- and Long-Term Development Plan for Medical Isotopes, the widespread adoption of nuclear medicine equipment, and the continuous emergence of novel radiopharmaceuticals, the radiopharmaceutical sector has entered its 2.0 era, characterized by rapid industry growth. As a new-generation player in China’s radiopharmaceutical field, Beijing Xiantong International Technology Co., Ltd. remains committed to working alongside colleagues in the nuclear medicine community to deliver more innovative radiopharmaceutical diagnostic and therapeutic products that improve patient outcomes and quality of life.”

Dr. Zou Guowen, Founder of Kaicheng Capital“Kaisheng Capital is honored to have served as the exclusive financial advisor, assisting Xiantong Medicine in successfully completing this mega-round financing. We appreciate the company’s trust and recognition, as well as the support from both new and existing shareholders for this financing round. The radiopharmaceutical market has seen growing enthusiasm year by year. Radiopharmaceutical products already launched abroad have demonstrated significant clinical efficacy, and the high barriers to R&D have led major multinational corporations (MNCs) to regard this sector as the next critical battleground in the pharmaceutical industry. As a leading innovator in China’s radiopharmaceutical sector, Xiantong Medicine has consistently maintained its leadership in integrating the entire upstream, midstream, and downstream value chain, continuously contributing to the development of domestic radiopharmaceuticals. We look forward to Xiantong Medicine’s continued expansion of boundaries, creating hope for patients worldwide.””

SDIC Venture Capital, established in 2016, is a venture capital fund management company specially set up by China State Development & Investment Corp. (SDIC) in accordance with market-oriented principles. It was founded to implement the national innovation-driven development strategy, deepen comprehensive strategic cooperation with the Ministry of Science and Technology, and accelerate the transfer and commercialization of national scientific and technological achievements. Through platforms such as the National Science and Technology Major Project Achievement Transformation Fund, the SDIC Beijing-Tianjin-Hebei Scientific and Technological Achievement Transformation Fund, the SDIC High-Tech (Shenzhen) Venture Capital Fund, the SDIC (Ningbo) Scientific and Technological Achievement Transformation Fund, and the SDIC (Guangdong) Scientific and Technological Achievement Transformation Fund, SDIC Venture Capital consistently focuses on investment goals related to the transformation of scientific and technological achievements. It targets key sectors including advanced manufacturing, electronic information, biopharmaceuticals, and materials and energy, while aligning with national regional development strategies such as the Beijing-Tianjin-Hebei region, the Yangtze River Delta, and the Guangdong-Hong Kong-Macao Greater Bay Area. The company is committed to continuously promoting breakthroughs in independent innovation of core key technologies and building a robust investment ecosystem for the transformation of scientific and technological achievements.

GoldStone Investment Co., Ltd. was established in 2007 as a wholly-owned subsidiary of CITIC Securities and was one of the first two enterprises approved by the China Securities Regulatory Commission (CSRC) to pilot direct investment operations. Over the past sixteen years, GoldStone Investment has been consistently ranked first among “Chinese Brokerage Private Equity Subsidiaries” and listed among the top ten “Private Equity Firms in China” by professional equity investment research institutions such as Zero2IPO and TouZhong, making it one of the most influential private equity investment firms in China. In 2022, GoldStone Investment initiated funds with a total scale exceeding RMB 10 billion. As the fund manager, GoldStone Investment supports enterprises aligned with national strategic emerging industry layouts and possessing core competitiveness through equity investments. In terms of investment activities, GoldStone Investment deployed nearly RMB 10 billion in external investments in 2022, covering multiple sectors including new materials, new energy, next-generation information technology, and healthcare. To date, GoldStone Investment manages more than 20 private equity funds.

The China State-owned Enterprise Structural Adjustment Fund, managed by Chengtong Fund Management Co., Ltd., is a national-level private equity investment fund established with the approval of the State Council and under the entrustment of the State-owned Assets Supervision and Administration Commission (SASAC). Led by China Chengtong Holdings Group Ltd., the fund was jointly initiated by other large central state-owned enterprises, local governments, and local state-owned enterprises. As a national-level private equity investment fund, the Structural Adjustment Fund remains committed to its mission of “serving the structural adjustment of state-owned enterprises and facilitating the innovative development of China’s economy.” With the objectives of optimizing the layout and structure of the state-owned economy and enhancing the industrial concentration of central state-owned enterprises, the fund deeply explores enterprise value and fully leverages the demonstrative and leading role of state-owned capital.

Genertec Venture Capital Co., Ltd. is an equity investment platform controlled by China General Technology (Group) Holding Co., Ltd. and operating under Genertec Capital. Leveraging its own capital and managed funds, it conducts equity investments aligned with the core businesses of China General Technology Group. With extensive investment experience and a track record of successful capital market transactions in advanced manufacturing and healthcare, Genertec Venture Capital has invested in and nurtured a portfolio of high-quality enterprises that represent the forefront of China’s technological innovation, possess independent R&D capabilities, and demonstrate global competitiveness.

Upholding the philosophy of investing in the future, innovation, and value, China Life Equity Investment leverages the professional advantages of insurance capital and fulfills China Life’s corporate responsibility to serve national strategies and support the real economy. Demonstrating China Life’s commitment to technological self-reliance and strength, China Life Equity Investment focuses on core technologies and has invested in numerous innovative high-tech enterprises that break foreign monopolies on technology and products and are dedicated to resolving critical “chokepoint” issues. The portfolio companies are distributed across key fields and pivotal links in the medical health and technological innovation industries, empowering a cohort of leading enterprises with significant voice and influence in industrial development, and striving to enhance the security and competitiveness of industrial and supply chains.

Wuxi Venture Capital is a state-owned venture capital firm integrating seed, angel, venture, equity, and M&A funds, with total assets under management exceeding RMB 200 billion. The firm focuses on strategic emerging industries strongly supported by national policies, including biopharmaceuticals, integrated circuits, dual-carbon energy conservation, and advanced manufacturing. Wuxi Venture Capital provides investment empowerment to high-quality enterprises across multiple financing stages, including angel, VC, PE, private placements, and mergers and acquisitions, offering investment services that cover the entire corporate lifecycle.

Wuxi Xinshang Capital was established in July 2021 with a registered capital of RMB 10 billion, serving as the core equity investment platform under Wuxi Taihu New City Development Group Co., Ltd. Xinshang Capital focuses on strategic emerging industries such as integrated circuits, digital economy, new energy, and general health. It has built a “one body, two wings” development pattern, with equity investment as the main body, supported by fund investment and investment banking, thereby forming an equity investment ecosystem covering Angel, VC, PE, and FOF stages.

WinX Capital is a leading investment bank in China’s healthcare sector, with headquarters in Beijing and Shanghai, covering more than 3,000 active institutional investors and industrial groups. It has received numerous accolades, including “No. 1 Financial Advisor in Healthcare for 2022” by First New Voice, “Top 2 Best Financial Advisors in Healthcare for 2021–2022” by Qimingpian & New Voice Innovation Services, and “Top 5 Healthcare Financial Advisor of the Year (2022–2023 Pengcheng Award)” by VCBeat.